Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (300760.SZ)
- Previous Close
299.77 - Open
304.68 - Bid 302.23 x --
- Ask 303.02 x --
- Day's Range
298.63 - 303.60 - 52 Week Range
253.48 - 316.10 - Volume
2,857,740 - Avg. Volume
3,443,911 - Market Cap (intraday)
366.727B - Beta (5Y Monthly) 0.10
- PE Ratio (TTM)
30.13 - EPS (TTM)
10.04 - Earnings Date May 10, 2024 - May 13, 2024
- Forward Dividend & Yield 10.30 (3.44%)
- Ex-Dividend Date May 28, 2024
- 1y Target Est
391.95
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. provides medical devices and solutions worldwide. The company offers patient monitoring and life support products, such as patient monitoring systems, electrocardiographs, defibrillators, anesthesia machines, ventilators, infusion pumps, surgical lights, operating tables, medical supply units, endoscopes, and accessories, as well as emergency care, peri-operative care, critical care, and IT solutions. It also provides in-vitro diagnostics products, including hematology and chemistry analyzers and reagents, chemiluminescence immunoassay products, hemoglobin systems, flow cytometry products, and micro plate readers and washers, as well as coagulation, urinalysis, and microbiology solutions; medical imaging systems comprising ultrasound and radiology products; and veterinary products. The company was founded in 1991 and is headquartered in Shenzhen, the People's Republic of China.
www.mindray.comRecent News: 300760.SZ
Performance Overview: 300760.SZ
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300760.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300760.SZ
Valuation Measures
Market Cap
363.45B
Enterprise Value
342.54B
Trailing P/E
29.85
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.11
Price/Book (mrq)
10.05
Enterprise Value/Revenue
9.53
Enterprise Value/EBITDA
25.03
Financial Highlights
Profitability and Income Statement
Profit Margin
33.86%
Return on Assets (ttm)
15.96%
Return on Equity (ttm)
34.23%
Revenue (ttm)
35.94B
Net Income Avi to Common (ttm)
12.17B
Diluted EPS (ttm)
10.04
Balance Sheet and Cash Flow
Total Cash (mrq)
21.19B
Total Debt/Equity (mrq)
0.78%
Levered Free Cash Flow (ttm)
5.91B